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Abstract
The small heterodimer partner (SHP) regulates fatty acid oxidation and lipogenesis in the
liver by regulating peroxisome proliferator-activated receptor (PPAR) γ expression. SHP is
also abundantly expressed in the myocardium. We investigated the effect of SHP expres-
sion on myocardia assessing not only heart structure and function but also lipid metabolism
and related gene expression in a SHP deletion animal model. Transcriptional profiling with a
microarray revealed that genes participating in cell growth, cytokine signalling, phospholipid
metabolism, and extracellular matrix are up-regulated in the myocardia of SHP knockout
(KO) mice compared to those of wild-type (WT) mice (nominal p value < 0.05). Consistent
with these gene expression changes, the left ventricular masses of SHP KO mice were sig-
nificantly higher than WT mice (76.8 ± 20.5 mg vs. 52.8 ± 6.8 mg, P = 0.0093). After 12
weeks of high fat diet (HFD), SHP KO mice gained less weight and exhibited less elevation
in serum-free fatty acid and less ectopic lipid accumulation in the myocardium than WT
mice. According to microarray analysis, genes regulated by PPARγ1 and PPARαwere
down-regulated in myocardia of SHP KO mice compared to their expression in WT mice
after HFD, suggesting that the reduction in lipid accumulation in the myocardium resulted
from a decrease in lipogenesis regulated by PPARγ. We confirmed the reduced expression
of PPARγ1 and PPARα target genes such as CD36, medium-chain acyl-CoA dehydroge-
nase, long-chain acyl-CoA dehydrogenase, and very long-chain acyl-CoA dehydrogenase
by SHP KO after HFD.
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Introduction
The small heterodimer partner (SHP) is an atypical orphan nuclear receptor that regulates the
expression of genes involved in glucose, lipid, and bile acid metabolism and plays a key role in
metabolic homeostasis [1, 2]. Interestingly, SHP-deficient mice exhibit increased fatty acid oxi-
dation (FAO) and decreased lipogenesis, and thus, are protected from diet-induced hepatic
steatosis [3–7]. This is associated with the activation of peroxisome proliferator-activated
receptor γ (PPARγ) by SHP [8]. In SHP-deficient mice, very low expression of PPARγ2, a
potent lipogenic transcription factor, decreases lipogenesis in the liver [7].
SHP is abundantly expressed not only in the liver but also in the myocardium. The heart is
one of the most energy-demanding organs in the body. Heart energy is primarily derived from
FAO, and long-chain fatty acids (LCFAs) are the preferred substrate for oxidative phosphory-
lation in cardiac mitochondria [9, 10]. To date, few studies have investigated the metabolic
role of SHP in the myocardium. One study found that the hearts of SHP-deficient mice were
hypertrophied and that SHP blocked the development of hypertrophy by interfering with
GATA6 signalling [11]. However, it was recently reported that SHP overexpression in cardio-
myocytes induced lipid accumulation, insulin resistance, and inflammation [12].
In the present study, we comprehensively profiled gene expression changes in the myocar-
dium via SHP knockout (KO) and investigated the effect of SHP deletion on the myocardium,
assessing not only heart structure and function but also lipid metabolism. We found that SHP-
deficient mice hearts hypertrophied without functional change and exhibited less ectopic lipid




The SHP-deficient mice (SHP KO) were kindly donated from Baylor College of Medicine
(Houston, TX, USA) with Dr. Moore’s permission. SHP KO mice were further backcrossed to
C57BL/6 mice (WT), which were purchased from Orient (Seongnam, Korea), at our laboratory
[7]. All mice were fed an ad libitum laboratory chow diet (CD, Purina irradiated laboratory
chow 38057, Purina Korea, Seoul, Korea) prior to the experiments. Five- to Six-week-old male
WT and SHP KO mice were fed a HFD (Research Diets D12079B, Research Diets, New Bruns-
wick, NJ, USA) for 12 weeks. The HFD included approximately 4.7 kcal/g, with 17% protein,
40% fat, and 43% carbohydrates. Each group included eight to ten mice, and the experiment
was repeated at least three times. All mice were housed in conventional plastic cages with free
access to food and water at 23 ± 2˚C, 60 ± 10% humidity, and a 12-h light/12-h dark photope-
riod. At the end of 12 weeks, mice were anaesthetized with an intraperitoneal injection of a mix-
ture of zolazepam/tiletamine (80 mg/kg; Zoletil 501, Virbac, France) and xylazine (20 mg/kg;
Rompun1, Bayer HealthCare, Germany) for tissue sampling after 8 h of fasting. Whole blood
samples were collected and the mice were sacrificed by excision of the heart under deep anaes-
thesia. All procedures involving the use of laboratory animals were in accordance with the
Guide for Standard Operation Procedures, and were performed after receiving approval from
the Institutional Animal Care and Use Committee (IACUC) of the Clinical Research Institute,
Seoul National University Bundang Hospital (approval No. BA1103-079/021-01).
Left Ventricle (LV) structure and function
Transthoracic echocardiography (M-mode two-dimensional echocardiography) was per-
formed on anaesthetized mice (1.8% isoflurane, inhalation) using a Philips iE33 ultrasound
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machine with a 15 mHz liner array transducer, at baseline, 6 weeks, and 12 weeks after HFD
feeding by an experienced cardiologist who was blinded to all groups. LV chamber dimensions
(LV end-diastolic dimension, LVEDD; LV end-systolic dimension, LVESD), LV wall thicknesses
(LV posterior wall, LVPWd; interventricular septum, IVS), fractional shortening (FS, calculated
as [(LVEDD–LVDSD)/LVEDD] × 100%) were analysed offline using dedicated software (Pro-
Solv Cardiovascular Analyzer version 3.5; ProSolv, Indianapolis, IN, USA) obtained from M-
mode traces. LV mass was calculated as [(IVS+LVPWd+LVEDD)3 –LVDSD3] × 1.055.
Measurement of body weight and blood glucose levels
Body weight was monitored every week until mice were sacrificed. Intraperitoneal glucose tol-
erance test (IPGTT) was carried out after 6 hours of fasting by intraperitoneal injection of 2 g/
kg glucose 12 weeks after HFD feeding. Blood glucose levels were determined from tail vein
blood by a glucometer (ACCU-CHEK Active, Roche, Mannheim, Germany) before and 15,
30, 60, 90, and 120 min after glucose injection.
Measurement of fatty acid oxidation (FAO) and oxygen consumption
(VO2)
To measure FAO, heart muscle tissues were lysed in an ice-cold mitochondria isolation buffer
(250 mM sucrose, 10 mM Tris-HCl, and 1 mM EDTA). Lysates were incubated for 2 h with
0.2 mM [1-14C] palmitate. 14CO2 and
14C-labelled acid-soluble metabolites were quantified
using a liquid scintillation counter. Each cpm value was normalized by the protein content of
each lysate. Oxygen consumption rates (VO2) of mice were measured using a Columbus
Instruments Oxymax System (Columbus, OH, USA). Resting baseline oxygen consumption
rates were assessed for at least 1 h.
Histology and electron microscopic examination
Hearts were immediately isolated for histologic examination and fixed in 4% formaldehyde,
dehydrated, embedded in paraffin, and sectioned (4 μm). Sections were stained with haema-
toxylin and eosin (H&E). To evaluate the degree of interstitial fibrosis, cardiac collagen deposi-
tion was assessed by Masson’s trichrome stain (Alfred Pathology, Melbourne, Australia).
Images of the LV were obtained using an Olympus light microscope (Tokyo, Japan) at 40x
magnification. Collagen stained blue, was measured and analysed using Olympus Image-Pro
Plus version 6.0. The percentage of fibrosis observed was calculated by dividing the total area
of collagen by the total area of the LV and multiplying by 100%. Data were normalized to a
control value of 1 and presented as fold changes.
For transmission electron microscopic examination, heart tissues were dissected, cut into
small sections (1 × 1 mm), and immersed in 2.5% glutaraldehyde at 4˚C. We calculated the
ratio of lipid droplet areas to unit heart muscle area in transmission electron microscopy sec-
tions using by Axiovision 4 Imaging/Archiving software (Axiovision 4, Carl Zeiss, Germany).
To compare mitochondrial morphology and density among the groups, a blind assessment
was performed by a pathologist who randomly selected 10 mitochondria at 3 sites per group
and measured long diameters of the cut surfaces.
Microarray experiment and pathway analysis
Total RNA was purified from heart muscle tissue using RNeasy mini kit (Qiagen, Hilden, Ger-
many). Fragmented biotinylated cRNAs were then generated according to the standard Affy-
metrix protocol (Affymetrix, Santa Clara, CA, USA). They were hybridized to Affymetrix
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GeneChip1 Mouse Gene 1.0 ST arrays covering 28,853 annotated genes. The fluorescent sig-
nal on the array was scanned using a GeneChip1 Scanner to produce probe intensities. The
log2-probe-intensities were normalized and then summarized into log2-probeset-intensities
using Robust Multiarray Average [13], part of the Expression Console1 software (Affyme-
trix). To identify differentially expressed genes, we performed permutation tests to calculate p
values for differential expression. Gene set enrichment analysis (GSEA) [14] was carried out to
identify differentially regulated pathways in each group. A total of 1,330 gene sets from public
biological pathway databases, or C2 gene sets from mSigDB [14] were analysed for differential
regulation. Gene sets or pathways with nominal p values < 0.05 were visualized with network
representation by Enrichment Map [15], where two gene sets were connected with an edge if
the Jaccard coefficient was greater than > 0.6. The microarray data from this publication have
been submitted to the ArrayExpress database (https://www.ebi.ac.uk/arrayexpress/) and
assigned the identifier E-MTAB-5329.
Quantitative real-time polymerase chain reaction (RT-PCR)
cDNA was synthesized using M-MLV reverse transcriptase (Invitrogen, Carlsbad, CA, USA).
Quantitative RT-PCR was performed using the ABI 7500 Real-Time PCR System (Applied Biosys-
tems, Foster City, CA, USA), and amplification was achieved using the SYBR Premix Ex Taq poly-
merase (Takara, Otsu, Japan). Gene-specific primers for c-fos, c-Jun-N-terminal kinase (c-jun), early
growth response 1 (egr-1), brain natriuretic peptide (BNP), actin a1 skeletal muscle (Acta1), sarco/
endoplasmic reticulum Ca2+-transport ATPase2a (Serca2a), Forkhead box O3 (FOXO3), Phospha-
tase and tensin homolog (PTEN), PPARγ1, cluster of differentiation 36 (CD36, fatty acid translo-
case), medium-chain acyl-CoA dehydrogenase (MCAD), long-chain acyl-CoA dehydrogenase
(LCAD), very long-chain acyl-CoA dehydrogenase (VLCAD), glucose transporter 1(GLUT1), glu-
cose transporter 4 (GLUT4), and pyruvate dehydrogenase kinase 4 (PDK4) (Cosmo Genetech,
Seoul, Korea) were designed using Primer Express software (Applied Biosystems). Primer sequences
are described in S1 Table. The relative expression of all genes was normalized to both beta actin and
18S RNA, and no differences between normalized levels were found. Therefore, the levels normal-
ized to beta actin are presented.
Statistical analysis
Results are reported as mean ± standard deviation (SD). Figures are presented as mean ± stan-
dard error of the mean (SEM). Statistical analysis was performed with the Mann-Whitney test.
Statistical significance was determined at P< 0.05.
Results
SHP KO causes cardiac hypertrophy
Transcriptional profiling with microarrays revealed that pathways involved in cell growth,
cytokine signalling, phospholipid metabolism, and extracellular matrix (ECM) were up-regu-
lated in the heart tissue of SHP KO mice compared to in WT mice (Fig 1) under control diets.
Interestingly, we found that the PI3K and AKT pathways were also activated in the hearts of
SHPKO mice compared to those of WT mice. We used RT-PCR to confirm up-regulation of
the proto-oncogenes c-fos, c-jun, and egr-1, the end products of various signal transduction
pathways, in the myocardia of SHP KO mice (Fig 2A). Consistent with the increased expres-
sion of cell growth-related proto-oncogenes, SHP KO mice exhibited higher LV masses than
the WT mice (76.8 ± 20.5 mg vs. 52.8 ± 6.8 mg, P = 0.0093), reflecting cardiac hypertrophy,
although there was no difference in ejection fraction or fractional shortening of SHP KO and
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WT mice (Table 1). However, we did not observe increases in the expression of hypertrophy
genes, such as BNP, Acta1, and Serca2a, in the hypertrophied myocardia of SHP KO mice (Fig
2B). In addition, despite the increase in cytokine signalling or ECM-related pathway genes, no
significant changes in the infiltration of inflammatory cells or fibrosis were observed in myo-
cardial tissue from SHP KO mice (Fig 2C).
HFD causes cardiac hypertrophy in WT mice but not in SHP KO mice
When SHP KO and WT mice were fed with HFD for 12 weeks, SHP KO mice gained less
weight than WT mice without significant changes in blood glucose after 4 weeks (Fig 3A
and 3B). HFD WT mice exhibited cardiac hypertrophy when compared to CD WT mice
(80.6 ± 22.5 mg vs. 52.8 ± 6.8 mg, P = 0.0227, Table 1), although neither cardiac functional
derangements (Table 1) nor increased expression of pathological hypertrophic genes (Fig 2A)
were observed. Interestingly, no additional hypertrophy was observed for up to 12 weeks after
HFD treatment in SHP KO mice. Transcriptome analysis showed that signal transduction
pathways, especially insulin signalling, were down-regulated in HFD WT myocardia (S1 Fig).
RT-PCR confirmed that FOXO3, which is repressed by insulin signalling, and PTEN, a nega-
tive regulator of insulin signalling, also increased after HFD (Fig 3C). This suggests that ele-
vated insulin resistance may explain the cardiac hypertrophy observed in HFD WT mice
(Table 1). SHP expression was significantly increased in the HFD WT myocardia compared to
that in the CD WT myocardia (P = 0.006, Fig 3D).
Fig 1. Network of significantly altered biological pathways in the myocardia of SHP KO mice compared to in WT mice. Nodes represent gene
sets or pathways, and edges are connected if the two gene sets share a significant number of genes (Jaccard coefficient > 0.6). Gene sets with up-
regulated and down-regulated genes in SHP KO mice are coloured red and blue, respectively.
https://doi.org/10.1371/journal.pone.0186021.g001
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Fig 2. Changes in gene expression induced by SHP deficiency and/or HFD feeding and myocardial histologies. (A)
Expression of cell growth-related genes c-jun, c-fos, and egr-1. n = 5–8 per group; * p < 0.05 compared to CD WT mice, **
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SHP KO attenuates HFD-induced lipid accumulation in myocardia
We observed significantly less ectopic lipid accumulation in the myocardial tissue of SHP KO
mice (P< 0.01) (Fig 4A), and oxygen consumption and FAO tended to be lower in the myo-
cardia of SHP KO mice, although these trends were not statistically significant (Fig 4B). We
found that the long diameters of the mitochondria cut surfaces were not significantly dif-
ferent in the hearts of SHPKO (median of 1.47 μm, range = 0.72–2.06 μm) versus WT
(median of 1.22 μm, range = 0.67–2.11 μm) mice. Further, there were no significant differ-
ences in mitochondrial morphology and density (S2 Fig), and no abnormal material accu-
mulation was observed. Next, we investigated transcriptional changes in the hearts of SHP
KO mice compared to in WT mice after HFD. Table 2 shows the list of pathways signifi-
cantly down-regulated in the myocardia of SHP KO mice. PPARγ1 and PPARα target
genes were down-regulated in SHP KO myocardia after HFD, suggesting that the decrease
in lipogenesis after SHP KO may explain the decrease in myocardial lipid accumulation.
We confirmed the reduced expression of the PPARγ1 and PPARα target genes CD36,
MCAD, LCAD, and VLCAD in SHP KO mice (Fig 4C). Moreover, SHP KO mice exhibited
less elevation in serum free fatty acid compared with WT mice after HFD (859.4 ± 166.3
mg/dL vs. 720.0 ± 62.0 mg/dL, P = 0.005). To evaluate substrate preference between free
fatty acid and glucose in myocardia, the expression of GLUTs and PDK4 were examined.
We found that the transcriptional level of PDK4 was profoundly decreased in the hearts of
SHP KO mice compared to that of WT mice (P < 0.001, Fig 4D), and we found marginally
increased expression of GLUT1 in the hearts of HFD SHP KO mice compared to that of
CD SHP KO mice (Fig 4D). However, the expression of GLUT1 and GLUT4 in the heart
was not different between WT and SHP KO mice.
p < 0.05 compared to HFD WT mice. c-jun, c-Jun-N-terminal kinase; egr-1, early growth response 1. (B) Expression of
pathologic hypertrophic markers BNP, Acta1, and Serca2a, normalized to β-actin. n = 5–8 per group; * p < 0.05 compared to
CD WT mice, † p < 0.05 compared to CD SHP KO mice. BNP, brain natriuretic peptide; Acta1, actin a1 skeletal muscle;
Serca2a, sarco/endoplasmic reticulum Ca2+-transport ATPase2a. (C) Myocardial histology of WT and SHP KO mice.
Representative myocardial sections of SHP KO mice and WT mice stained with haematoxylin and eosin (H&E). Original
magnification, ×200.
https://doi.org/10.1371/journal.pone.0186021.g002





SHP KO-CD (n = 8) SHP KO-HFD (n = 8)
Body weight (g) 28.7 ± 1.0 43.5 ± 3.6 31.6 ± 3.4 38.6 ± 3.6†
Heart weight (mg) 132.2 ± 10.7 155.6 ± 18.6 136.6 ± 14.8 134.6 ± 7.0‡
Heart weight/FL (mg/mm) 8.2 ± 0.7 9.6 ± 1.0 8.5 ± 0.1 8.5 ± 0.5‡
LV mass (mg) 52.8 ± 6.8 80.6 ± 22.5* 76.8 ±20.5* 73.9 ± 19.9*
LV mass/FL (mg/mm) 3.3 ± 0.4 5.0 ± 1.4 4.8 ± 1.3 4.2 ± 0.7
IVSd (mm) 0.76 ± 0.09 0.76 ± 0.09 0.88 ± 0.10 0.83 ± 0.10
LVPWd (mm) 0.78 ± 0.11 0.89 ± 0.14 0.86 ± 0.15 0.88 ±0.13
Fractional shortening (%) 62.8 ± 5.5 65.9 ± 5.0 58.7 ± 3.3 63.7 ± 7.6
Ejection fraction (%) 94.6 ± 2.4 95.8 ± 1.7 92.9 ± 1.8 94.6 ± 3.5
Data are means ± SD. FL, femur length; LV, left ventricle; IVSd, Interventricular septal distance; LVPWd, Left ventricular posterior wall distance
* p < 0.05 vs. WT-CD mice.
†p < 0.05 vs. SHP KO-CD mice
‡ P < 0.05 vs. WT-HFD mice
https://doi.org/10.1371/journal.pone.0186021.t001
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Discussion
In the present study, SHP deficiency induced cardiac hypertrophy, and consistent with this,
up-regulation of genes involved in cell growth, cytokine signalling, phospholipid metabolism,
and ECM in the heart tissue of SHP KO mice. These effects were associated with a decrease in
plasma free fatty acid levels and reduced deposition of fat in the myocardia of HFD SHP KO
mice. SHP deficiency did not increase O2 consumption or FAO in myocardia. PPARγ1 and
PPARα target genes were down-regulated in the myocardia of HFD SHP KO mice, and
Fig 3. Glucose tolerance and changes in insulin resistance-related genes in the myocardia of WT and SHP KO mice after 12
weeks of HFD feeding. (A) Growth curves in mice. *p < 0.05, ** p < 0.001. (B) Intraperitoneal glucose tolerance tests (IPGTTs) (2 g D-
glucose per kg body weight) were performed in 17- to 18-week-old male mice. (C) Relative expression of insulin signalling-related genes
FOXO3 and PTEN. n = 5–8 per group; * p < 0.05 compared to CD WT mice, † p < 0.05 compared to CD SHP KO mice. FOXO3,
forkhead box O3; PTEN, phosphatase and tensin homolog. (D) Relative expression of SHP in WT mice myocardia. n = 5–8 per group; *
p < 0.05 compared to CD WT mice.
https://doi.org/10.1371/journal.pone.0186021.g003
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expression levels of several key genes involving fatty acid uptake, oxidation, and synthesis were
decreased in the hearts of HFD SHP KO mice compared with levels in HFD WT mice.
In the liver, sustained SHP expression results in depletion of the hepatic bile acid pool and
triglyceride accumulation. In contrast, SHP deficiency is associated with reduced hepatic cho-
lesterol, triglyceride, and free fatty acid levels compared to WT levels [7, 16]. Moreover, SHP-
deficient mice exhibit increased fatty acid oxidation and decreased lipogenesis; thus, they are
protected from diet-induced hepatic steatosis by very low expression of PPARγ2 [7]. These
findings in the liver are in partial agreement with those in the myocardium in terms of the
reduced lipid deposition. It could be possible through down-regulated expressions of PPARγ
target genes. Unlike in the liver, in the myocardia of HFD SHP KO mice, FAO was not
increased but the expression levels of PPARγ1, CD36,MCAD, and LCAD, key genes involved
in fatty acid uptake and oxidation, were significantly decreased according to the present study.
These findings could reflect the down-regulation of PPARα target genes. In agreement with
our findings, PPARα-deficient mice were previously reported to exhibit age-associated cardiac
fibrosis, diminished rates of FAO, and a lack of cellular fasting responses [17, 18]. MCAD is
pivotal in catalyzing mitochondrial FAO and decreased MCAD expression was reported in
pressure overload in vivo models [19, 20]. Consistent with these findings, the expression of
MCAD was also reduced in the hearts of SHP KO mice in the present study. While a decrease
in FAO in the myocardium can induce cardiac fat accumulation, reduced lipid accumulation
Fig 4. Myocardial lipid accumulation, FAO, and related gene expression in the myocardia of WT and SHP KO mice after 12 weeks of HFD
feeding. (A) Lipid droplets in the myocardia of HFD SHP KO and HFD WT mice. Transmission electron microscope images in HFD SHP KO and
HFD WT mice and calculated areas of lipid droplets per unit cardiac muscle. Magnifications of large pictures are 10,000× and those of small ones are
500,000×. n = 8 per group; *p < 0.01. (B) Myocardial fatty acid oxidation and VO2 max in SHP KO and WT mice fed with HFD. n = 5–8 per group. (C)
Expression of PPARγ1 and PPARα target genes CD36, MCAD, LCAD, and VLCAD in HFD SHP KO mice. n = 5–8 per group; *p < 0.05 compared to
corresponding WT mice. PPARγ1, peroxisome proliferator-activated receptor γ1; CD36, cluster of differentiation; MCAD, medium-chain acyl-CoA
dehydrogenase; LCAD, long-chain acyl-CoA dehydrogenase; VLCAD, very long-chain acyl-CoA dehydrogenase. (D) Expression of GLUTs and
PDK4 in WT and SHP KO mice. n = 5–8 per group; *p < 0.05 compared to corresponding WT mice. GLUT1, glucose transporter 1; GLUT4, glucose
transporter 4; PDK4, pyruvate dehydrogenase kinase 4.
https://doi.org/10.1371/journal.pone.0186021.g004
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Table 2. The list of gene sets down-regulated in heart tissue from SHP KO HFD mice compared to that from WT HFD mice (nominal P
values < 0.001).
Name Description Size ES NES
INTRINSIC PATHWAY (BIOCARTA) Intrinsic prothrombin activation pathway 22 -0.88 -1.15
FORMATION OF FIBRIN CLOT CLOTTING
CASCADE (REACTOME)
Genes involved in formation of fibrin clot (clotting cascade) 29 -0.85 -1.25
INTRINSIC PATHWAY (REACTOME) Intrinsic prothrombin activation pathway 15 -0.83 -1.39
PHENYLALANINE METABOLISM (KEGG) Phenylalanine metabolism 16 -0.78 -1.20
BIOSYNTHESIS OF UNSATURATED FATTY
ACIDS (KEGG)
Biosynthesis of unsaturated fatty acids 18 -0.67 -1.05
SELENOAMINO ACID METABOLISM (KEGG) Selenoamino acid metabolism 24 -0.65 -1.20
EPHRINB REV PATHWAY (PID) Ephrin B reverse signaling 29 -0.63 -1.47
PPARA PATHWAY (BIOCARTA) Mechanism of gene regulation by peroxisome proliferators via PPARa(alpha) 54 -0.61 -1.63
PROPANOATE METABOLISM (KEGG) Propanoate metabolism 29 -0.61 -1.41
CITRIC ACID CYCLE TCA CYCLE (REACTOME) Genes involved in citric acid cycle (TCA cycle) 18 -0.58 -1.41
GLYPICAN 1PATHWAY (PID) Glypican 1 network 24 -0.52 -1.38
AMINO ACID SYNTHESIS AND
INTERCONVERSION TRANSAMINATION
(REACTOME)
Genes involved in amino acid synthesis and interconversion (transamination) 16 -0.52 -1.35
PPARG 01 Genes having at least one occurrence of the transcription factor binding site V
$PPARG_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around
their transcription start sites
33 -0.48 -1.42
PYRUVATE METABOLISM AND CITRIC ACID TCA
CYCLE (REACTOME)
Genes involved in pyruvate metabolism and citric Acid (TCA) cycle 37 -0.48 -1.68
GGTAACC, MIR-409-5P Genes having at least one occurrence of the motif GGTAACC in their 3’
untranslated region. The motif represents putative target of human mature
miRNA hsa-miR-409-5p (v7.1 miRBase)
30 -0.47 -1.53
METABOLISM OF VITAMINS AND COFACTORS
(REACTOME)
Genes involved in metabolism of vitamins and cofactors 46 -0.46 -1.24
GLUTAMATE NEUROTRANSMITTER RELEASE
CYCLE (REACTOME)
Genes involved in glutamate neurotransmitter release cycle 15 -0.44 -1.29
PPARA 01 Genes having at least one occurrence of the transcription factor binding site V
$PPARA_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their
transcription start sites
32 -0.42 -1.37
INTEGRIN CELL SURFACE INTERACTIONS
(REACTOME)
Genes involved in integrin cell surface interactions 75 -0.41 -1.42
PTEN PATHWAY SA PTEN is a tumor suppressor that dephosphorylates the lipid messenger
phosphatidylinositol triphosphate
17 -0.40 -1.40
RYAAAKNNNNNNTTGW UNKNOWN Genes having at least one occurrence of the highly conserved motif M151
RYAAAKNNNNNNTTGW in the region spanning up to 4 kb around their
transcription start sites. The motif does not match any known transcription
factor binding site
73 -0.35 -1.31
NECTIN PATHWAY (PID) Nectin adhesion pathway 29 -0.35 -1.36
FXR Q3 Genes having at least one occurrence of the transcription factor binding site V
$FXR_Q3 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their
transcription start sites
100 -0.32 -1.16
E2F Q2 Genes having at least one occurrence of the transcription factor binding site V
$E2F_Q2 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their
transcription start sites
147 -0.31 -1.45
GGCACTT, MIR-519E Genes having at least one occurrence of the motif GGCACTT in their 3’
untranslated region. The motif represents putative target (i.e., seed match) of
human mature miRNA hsa-miR-519e (v7.1 miRBase)
109 -0.30 -1.52
COUP DR1 Q6 Genes having at least one occurrence of the transcription factor binding site V
$COUP_DR1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb
around their transcription start sites
208 -0.30 -1.34
TGFB PATHWAY (BIOCARTA) TGF beta signaling pathway 18 -0.30 -1.15
(Continued )
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was observed in the present study. This may be the result of an indirect effect of low levels of
plasma free fatty acids from the liver or adipose tissue due to down-regulation of PPARγ target
gene expression. In agreement with these findings, SHP overexpression in cardiomyocytes has
been reported to induce lipid accumulation, which was accompanied with increased CD36
and PPARγ expression [12]. We also observed that SHP mRNA levels are induced in the hearts
of WT mice fed with HFD, as shown in the previous study. Nam et al., however, reported that
metformin induces SHP in an AMPK-independent manner, and that SHP is a novel anti-
hypertrophic regulator mediating the anti-hypertrophic role of metformin in the heart [11].
Admittedly, these findings are in contrast with ours in the present study. Regarding cardiac
hypertrophy, SHP has a beneficial role. As we reported in the current study, SHP loss is associ-
ated with cardiac hypertrophy. However, from the perspective of lipid metabolism, we also
found that SHP loss is beneficial with reduced ectopic lipid accumulation in the heart after
HFD. Therefore, whether SHP plays a beneficial role is dependent on the condition—cardiac
hypertrophy or lipid metabolism.
The process of selecting fatty acid or glucose for fuel in cells during the fed-fast cycle is
largely controlled by the pyruvate dehydrogenase complex, which is regulated by pyruvate
dehydrogenase kinase (PDK) and pyruvate dehydrogenase phosphatases [21]. Especially, a
role of PDK4 in cardiac hypertrophy and dilated cardiomyopathy has been reported [22–24].
In the present study, we observed a profound decrease in the expression of PDK4 in the hearts
of SHP KO mice. We propose that the reduction in plasma free fatty acids caused by decreased
expression of PPARγ1 or PPARα could reduce the expression of PDK4.
Table 2. (Continued)
Name Description Size ES NES
MAZ Q6 Genes having at least one occurrence of the transcription factor binding site V
$MAZ_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their
transcription start sites
169 -0.29 -1.39
DBP Q6 Genes having at least one occurrence of the transcription factor binding site V
$DBP_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their
transcription start sites
212 -0.26 -1.26
AUTODEGRADATION OF CDH1 BY CDH1 APC C
(REACTOME)
Genes involved in autodegradation of Cdh1 by Cdh1:APC/C 51 -0.25 -1.37
GCGSCMNTTT UNKNOWN Genes having at least one occurrence of the highly conserved motif M164
GCGSCMNTTT in the region spanning up to 4 kb around their transcription
start sites. The motif does not match any known transcription factor binding site
55 -0.25 -1.21
USF2 Q6 Genes having at least one occurrence of the transcription factor binding site V
$USF2_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their
transcription start sites
218 -0.23 -1.13
GATA1 02 Genes having at least one occurrence of the transcription factor binding site V
$GATA1_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their
transcription start sites
210 -0.22 -1.14
NFMUE1 Q6 Genes having at least one occurrence of the transcription factor binding site V
$NFMUE1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around
their transcription start sites
204 -0.19 -1.43
MYCMAX 03 Genes having at least one occurrence of the transcription factor binding site V
$MYCMAX_03 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around
their transcription start sites
212 -0.19 -1.11
ES, enrichment score; NES, normalized enrichment score; BIOCARTA, BioCarta pathway database; REACTOME, Reactome pathway database; KEGG,
KEGG pathway database; PID, Pathway Interaction Database; SA, Sigma-Aldrich pathway database; TRANSFAC, TRANSFAC database; miRBase,
microRNA database.
https://doi.org/10.1371/journal.pone.0186021.t002
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SHP functions predominantly as a transcriptional repressor of gene expression by
directly binding to a variety of nuclear receptors [1]. In our microarray experiment, vari-
ous signal transduction pathway genes were up-regulated by SHP KO. The end products of
various signal transduction pathways are proto-oncogenes, such as c-fos, c-jun, and egr-1,
which were significantly up-regulated in the myocardia of SHP KO mice. The de-repres-
sion of transcriptional regulators by SHP deletion may have caused cardiac hypertrophy
by activating these proto-oncogenes. Nam et al. reported that the GATA-6 signalling path-
way is responsible for cardiac hypertrophy following SHP deletion [11]. In the current
study, microarray analysis also confirmed that expression of GATA-6 target genes was
increased by SHP knockout (nominal p < 0.01). However, our genome-wide transcrip-
tional profiling study further suggests that the global increase in multiple signalling path-
way genes and proto-oncogenes induced by SHP knockout may explain the cardiac
hypertrophy observed in SHP KO mice.
It has been reported that activation of the PI3K and AKT pathways is important for cardio-
myopathy, especially when they are chronically activated [25]. In the present study, we found
that the PI3K and AKT pathways were activated in the hearts of SHP KO mice compared to
those of WT mice, suggesting a chronic activation of these pathways in the hearts of SHP KO
mice. This finding is different from that found from decreased acute activation of the PI3K
and AKT pathways in insulin resistance induced by a HFD or obesity.
Whereas cardiac hypertrophy by SHP deletion is associated with increases in multiple sig-
nalling pathways, the increase in the LV mass observed in HFD mice seems to result from the
development of insulin resistance. A previous study reported that FOXO is activated by HFD
and that diabetic cardiomyopathy, characterized by cardiac hypertrophy, is caused by insulin
resistance due to FOXO activation [26]. Although we failed to observe cardiac dysfunction
over 12 weeks of HFD, insulin resistance did develop, as demonstrated by increases in FOXO3
and PTEN levels. A longer treatment period (i.e. more than 6 months) or additional stimuli
such as a transverse aortic constriction will be needed to induce a more pronounced cardiac
phenotype [27–29].
A limitation of this study is that we cannot distinguish whether the observed metabolic
change in the myocardium of SHP-deficient mice is the result of a direct heart-specific effect
of SHP deletion or from a systemic correction of body metabolism, as we used a whole-body
SHP knockout model. A future study using cardiac-specific KO of SHP is warranted to clarify
the direct role of SHP deletion in the heart.
In conclusion, SHP-deficient mouse hearts exhibited hypertrophy but reduced ectopic lipid
accumulation after HFD, likely resulting from a decrease in lipogenesis regulated by PPARγ1.
Supporting information
S1 Fig. Network of significantly altered biological pathways in the myocardia of SHP KO
mice compared to in WT mice after 12 weeks of HFD feeding. Nodes represent gene sets or
pathways, and edges are connected if the two gene sets share a significant number of genes
(Jaccard coefficient > 0.6). Gene sets with up-regulated and down-regulated genes in SHP KO
mice are coloured red and blue, respectively.
(TIF)
S2 Fig. Representative mitochondrial morphologies using electron microscopy (×25,000)
in WT mice and SHP KO mice. There were no significant differences in mitochondrial mor-
phology and density between WT mice and SHP KO mice.
(TIF)
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S1 Table. Primer sequences used in quantitative real-time polymerase chain reaction.
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